Vis enkel innførsel

dc.contributor.authorLie, Ingrid Anne
dc.contributor.authorWesnes, Kristin
dc.contributor.authorKvistad, Silje S.
dc.contributor.authorBrouwer, Iman
dc.contributor.authorWergeland, Stig
dc.contributor.authorHolmøy, Trygve
dc.contributor.authorMidgard, Rune
dc.contributor.authorBru, Alla Nikolajevna S
dc.contributor.authorEdland, Astrid
dc.contributor.authorEikeland, Randi
dc.contributor.authorGosal, Sonia
dc.contributor.authorHarbo, Hanne-Cathrin Flinstad
dc.contributor.authorKleveland, Grethe
dc.contributor.authorSørenes, Yvonne
dc.contributor.authorØksendal, Nina
dc.contributor.authorBarkhof, Frederik
dc.contributor.authorVrenken, Hugo
dc.contributor.authorMyhr, Kjell-Morten
dc.contributor.authorBø, Lars
dc.contributor.authorTorkildesen, Øivind
dc.date.accessioned2023-01-20T12:43:37Z
dc.date.available2023-01-20T12:43:37Z
dc.date.created2022-08-11T16:07:13Z
dc.date.issued2022
dc.identifier.issn2332-7812
dc.identifier.urihttps://hdl.handle.net/11250/3044950
dc.description.abstractBackground and Objectives The relationship between smoking, long-term brain atrophy, and clinical disability in patients with multiple sclerosis (MS) is unclear. Here, we assessed long-term effects of smoking by evaluating MRI and clinical outcome measures after 10 years in smoking and nonsmoking patients with relapsing-remitting MS (RRMS). Methods We included 85 treatment-naive patients with RRMS with recent inflammatory disease activity who participated in a 10-year follow-up visit after a multicenter clinical trial of 24 months. Smoking status was decided for each patient by 2 separate definitions: by serum cotinine levels measured regularly for the first 2 years of the follow-up (during the clinical trial) and by retrospective patient self-reporting. At the 10-year follow-up visit, clinical tests were repeated, and brain atrophy measures were obtained from MRI using FreeSurfer. Differences in clinical and MRI measurements at the 10-year follow-up between smokers and nonsmokers were investigated by 2-sample t tests or Mann-Whitney tests and linear mixed-effect regression models. All analyses were conducted separately for each definition of smoking status. Results After 10 years, smoking (defined by serum cotinine levels) was associated with lower total white matter volume (β = −21.74, p = 0.039) and higher logT2 lesion volume (β = 0.22, p = 0.011). When defining smoking status by patient self-reporting, the repeated analyses found an additional association with lower deep gray matter volume (β = −2.35, p = 0.049), and smoking was also associated with a higher score (higher walking impairment) on the log timed 25-foot walk test (β = 0.050, p = 0.039) after 10 years and a larger decrease in paced auditory serial addition test (attention) scores (β = −3.58, p = 0.029). Discussion Smoking was associated with brain atrophy and disability progression 10 years later in patients with RRMS. The findings imply that patients should be advised and offered aid in smoking cessation shortly after diagnosis, to prevent long-term disability progression.en_US
dc.language.isoengen_US
dc.publisherLippincott, Williams & Wilkinsen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleThe Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosisen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.source.articlenumbere200008en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1212/NXI.0000000000200008
dc.identifier.cristin2042531
dc.source.journalNeurology, Neuroimmunology and Neuroinflammationen_US
dc.identifier.citationNeurology, Neuroimmunology and Neuroinflammation. 2022, 9 (5), e200008.en_US
dc.source.volume9en_US
dc.source.issue5en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal